Quintrio
Home

SERVICES-MISC HEALTH & ALLIED SERVICES, NEC

Mangoceuticals, Inc. Common Stock

MGRX

Mangoceuticals Inc focuses on developing, marketing, and selling a variety of men's wellness products and services through a telemedicine platform. The company's platform provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including Mango ED products.

Last trade $0.1584
Day change -$0.0019 (-1.19%)
Day range $0.155 – $0.172
Volume 317,912
Market cap $4M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$3.56M
Price / earnings
—
Price / book
0.26×
Price / sales
8.58×
EV / sales
8.16×
EV / EBITDA
-0.23×

Profitability

Earnings per share
-$0.90
Return on assets
-139.03%
Return on equity
-149.07%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
0.29×
Quick ratio
0.29×
Cash ratio
0.24×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$4.89M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for MGRX, quarterly periods
Line itemQ1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024Q2 FY2024 Jun 30, 2024
Revenue$67.86K$94.36K$84.25K$168.11K$109.31K$105.25K$133.37K$163.16K
Cost of revenue$8.22K$46.89K$33.35K$78.16K$24.74K$25.14K$50.7K$93.37K
Gross profit$59.65K$47.48K$50.9K$89.95K$84.57K$80.1K$82.67K$69.79K
Selling, general and administrative$1.5M$11.18M$958.71K$5.25M$2.17M$3.62M$1.02M$2.2M
Research and development$0$0$0$0$0$0$0$0
Total operating expenses$1.81M$1.66M$7.59M$5.36M$3.89M$2.01M$2.08M$2.24M
Operating income-$1.76M-$1.62M-$7.54M-$5.27M-$3.81M-$1.93M-$2M-$2.17M
Interest expense$0-$19.66K-$75.85K-$21.7K$13.7K-$13.7K$0-$222.68K
Income before taxes-$3.4M-$2.77M-$7.62M-$5.42M-$4.84M-$1.95M-$2M-$2.39M
Income taxes$0$0$0$0$0$0$0$0
Net income-$3.4M-$2.77M-$7.62M-$5.42M-$4.84M-$1.95M-$2M-$2.39M
Net income attributable to common shareholders-$3.7M-$3.06M-$7.91M-$5.42M-$5.13M-$1.95M-$2.29M-$2.39M
EBITDA-$1.46M-$1.04M-$7.52M-$4.43M-$3.39M-$1.21M-$2.03M-$2.14M
Basic earnings per share-$0.22-$0.21-$0.69-$0.57-$1.12-$0.75-$1.14-$1.37
Diluted earnings per share-$0.22-$0.21-$0.69-$0.57-$1.12-$0.75-$1.14-$1.37

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Mangoceuticals Secures $2.5 Million Strategic Investment in MangoRx IP Holdings; Receives Initial $1.75 Million Tranche

Mangoceuticals announced that its subsidiary MangoRx IP Holdings has secured $2.5 million in strategic investment from two investors for a 25% membership interest. The initial $1.75 million tranche has been received, with the remaining $750,000 due by November 28, 2026. The investment will fund commercialization of the company's antiviral intellectual property portfolio covering oral-surface administered preparations, with potential applications in poultry, livestock, and human oral-care markets valued at approximately $74.6 billion combined.

GlobeNewswire Inc.

Mangoceuticals Announces Lawsuit Seeking Damages Exceeding $73 Million Against Former Technology Consulting and Software Development Firm, Clarity Ventures, Inc.

Mangoceuticals filed a civil lawsuit against former technology consulting firm Clarity Ventures seeking over $73 million in damages for failure to deliver a fully functional, HIPAA-compliant ERP and eCommerce platform. Clarity has denied allegations and asserted counterclaims for unpaid invoices, which Mangoceuticals disputes. The company has since independently developed its own proprietary telehealth platform.

GlobeNewswire Inc.

Mangoceuticals, Inc. Announces PCT Patent Filing for MGX-0024 Antiviral Technology to Include Inhibiting Respiratory or Orally Acquired Virus Infection in Animals or Birds

Mangoceuticals, Inc. filed a PCT international patent application on February 26, 2026, to secure global patent protection for MGX-0024, an antiviral animal feed and drinking water additive. The filing follows recent clinical trial results showing zero respiratory-related mortality in 29,000 birds and prophylactic benefits against H5N1. The technology is already protected in the U.S. and has pending patents in major markets including the EU, Canada, China, India, Australia, and Japan.

GlobeNewswire Inc.

Mangoceuticals Announces Strategic Entry into High Growth Pouch Industry Through Acquisition of Smokeless Technology IP and Appointment of Tim Corkum Ex Philip Morris Executive to Lead High Growth Pouch Division

Mangoceuticals, a health and wellness company, has acquired the intellectual property and assets of Smokeless Technology Corp., a Canadian-based pouch innovation company. This acquisition will allow Mangoceuticals to expand into the growing oral pouch delivery market. The company has also appointed Tim Corkum, a former executive at Philip Morris, to lead its high-growth pouch division.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 16, 20241-for-15reverse split